2016 Fiscal Year Final Research Report
Inhibition of prostatic cancer through degradation of androgen receptor by effects of dioxin receptor ligand
| Project/Area Number |
26462391
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 前立腺癌 / ダイオキシン受容体 / 芳香族炭化水素受容体 / アンドロゲン受容体 / Indirubin |
|---|
| Outline of Final Research Achievements |
The expression status of the dioxin receptor (AhR) in the cell line including the human prostate cancer was confirmed by Western blot analysis. LNCaP, which is known as prostate cancer cell line, proliferation is controlled for indirubin or 3- Methylcholanthrene (3MC) as a typical AhR ligand, and the proliferation potency and the transcriptional ability of these ligands were confirmed, and androgen receptor (AR) appearance has decreased. The concentration dependency was admitted. Nude mice had been administrated these dioxin ligands through peritoneal injection. So, tolerated dose has been becoming clear. As a result, it was thought that the therapeutic gain to the hormone refractory prostate cancer was expected.
|
| Free Research Field |
：医歯薬学
|
